EA201991119A1 - Фармацевтическая композиция, способы лечения и ее применения - Google Patents

Фармацевтическая композиция, способы лечения и ее применения

Info

Publication number
EA201991119A1
EA201991119A1 EA201991119A EA201991119A EA201991119A1 EA 201991119 A1 EA201991119 A1 EA 201991119A1 EA 201991119 A EA201991119 A EA 201991119A EA 201991119 A EA201991119 A EA 201991119A EA 201991119 A1 EA201991119 A1 EA 201991119A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treatment
application
pharmaceutical composition
chronic kidney
Prior art date
Application number
EA201991119A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/078577 external-priority patent/WO2018087132A1/en
Publication of EA201991119A1 publication Critical patent/EA201991119A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способам лечения или предотвращения хронического заболевания почек и сердечно-сосудистого заболевания у пациентов с хроническим заболеванием почек, включающим введение пациенту эмпаглифлозина.
EA201991119A 2017-06-02 2017-11-08 Фармацевтическая композиция, способы лечения и ее применения EA201991119A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514249P 2017-06-02 2017-06-02
PCT/EP2017/078577 WO2018087132A1 (en) 2016-11-10 2017-11-08 Pharmaceutical composition, methods for treating and uses thereof

Publications (1)

Publication Number Publication Date
EA201991119A1 true EA201991119A1 (ru) 2019-11-29

Family

ID=68653647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991119A EA201991119A1 (ru) 2017-06-02 2017-11-08 Фармацевтическая композиция, способы лечения и ее применения

Country Status (1)

Country Link
EA (1) EA201991119A1 (ru)

Similar Documents

Publication Publication Date Title
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
MX2019002510A (es) Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201791898A1 (ru) Новые антитела, связывающиеся с tfpi, и содержащая их композиция
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
EA201791960A1 (ru) Применение лимоннокислого железа в лечении вызванной недостатком железа анемии
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений